PLG and Venous thrombosis: ACIBB (9.0, 18.0 and 36.0 mg/kg, i.v.), belonging to peptide, can significantly inhibit venous thrombosis in rats dose-dependently, by decreasing the contents of Fbg (fibrinogen) and PLg (plasminogen), increasing the activities of tPA (tissue plasminogen activator) and AT-III (antithrombin-III), as well as prolonging APTT (activated partial thromboplastin time), PT (prothrombin time) and TT [69].